StockData
TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Tenaya Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.38−0.00 (-0.81%)

Close on Oct 19, 2026

Market cap
$82.16M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 9, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 5, 2026After market close–––
Q1 FY2026
Ended Mar 31, 2026
May 6, 2026After market close$225.00K$-0.09–
Q4 FY2025
Ended Dec 31, 2025
Mar 11, 2026After market close–––
Q3 FY2025
Ended Sep 30, 2025
Nov 10, 2025Before market open–$-0.12–
Q2 FY2025
Ended Jun 30, 2025
Aug 6, 2025After market close–$-0.14–
Q1 FY2025
Ended Mar 31, 2025
May 7, 2025After market close–––
Q4 FY2024
Ended Dec 31, 2024
Mar 10, 2025After market close–$-0.28–
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024After market close–$-0.30–
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024After market close–$-0.34–
Q1 FY2024
Ended Mar 31, 2024
May 14, 2024After market close–$-0.40–
Q4 FY2023
Ended Dec 31, 2023
Mar 18, 2024After market close–$-0.40–

Company guidance

Outlook given with results on May 7, 2025, compared with the previous outlook

MeasurePeriodGuidancevs. prior
aggregate charges, primarily related to employee cash severance and continuing health benefitsby the end of the third quarter of 2025$1.60M to $2.70MNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Tenaya Therapeutics filed with the SEC